文献速递创伤与烧伤复苏、休克与脓毒症重症综合管理与镇静镇痛

凝血因子浓缩物治疗创伤性凝血病的疗效:系统评价与Meta分析

THE EFFICACY OF COAGULATION FACTOR CONCENTRATES IN THE MANAGEMENT OF PATIENTS WITH TRAUMA-INDUCED COAGULOPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS.
PubMed 文献 · Shock · 2024-12-19
一句话结论系统评价与Meta分析显示,纤维蛋白原浓缩物、凝血酶原复合物及两者联用未显著降低创伤性凝血病患者死亡率,但减少了输血量。

该系统评价与Meta分析纳入4项随机对照试验和7项观察性研究,评估血液成分制品与氨甲环酸对伴有创伤性凝血病的严重创伤患者的作用,主要结局为全因死亡率和输血量。结果显示,纤维蛋白原浓缩物(FC)、凝血酶原复合物(PCC)及FC+PCC联用均未显著降低死亡率;FC、PCC及FC+PCC均显著减少入院后红细胞输注,PCC还减少住院期间新鲜冰冻血浆输注。FC+PCC组、PCC组和rFVIIa组血栓事件发生率未显著升高,FC组和FC+PCC组多器官衰竭发生率较低但未达统计学显著。作者指出创伤性凝血病定义异质性大,证据确定性不足,需进一步开展高质量试验。

要点

  • FC、PCC及FC+PCC联用均未显著降低创伤性凝血病患者死亡率。
  • FC、PCC及FC+PCC均显著减少入院后红细胞输注;PCC还减少住院期间新鲜冰冻血浆输注。
  • FC+PCC组、PCC组和rFVIIa组血栓事件发生率未显著升高。
  • FC组和FC+PCC组多器官衰竭发生率较低,但未达统计学显著。
  • 创伤性凝血病定义异质性大,证据确定性不足,需进一步开展高质量试验。

适用人群与场景

  • 需要输血的严重创伤并伴有创伤性凝血病(有详细定义)的患者。

诊断标准与关键阈值

  • 创伤性凝血病的定义在纳入研究中异质性很大,作者呼吁统一普遍定义。

研究设计与关键结果

  • 研究类型为系统评价与Meta分析,纳入4项随机对照试验和7项观察性研究进行定性合成。
  • FC、PCC及FC+PCC给药均未显著降低死亡率。
  • FC、PCC及FC+PCC给药均显著减少入院后红细胞输注。
  • PCC给药减少住院期间新鲜冰冻血浆输注。
  • FC+PCC组、PCC组和rFVIIa组血栓事件发生率未显著升高。
  • FC组和FC+PCC组多器官衰竭发生率较低,但未达统计学显著。

证据类型、等级与局限

  • 证据类型为系统评价与Meta分析,纳入随机对照试验和非随机对照试验。
  • 作者指出证据确定性不高,需进一步开展设计良好的试验研究血液成分制品(特别是FC和PCC补充)对创伤性凝血病的疗效。
  • 局限:创伤性凝血病的定义异质性很大。

对床旁实践的改变

  • 作者认为,FC和PCC未能显著降低死亡率,但FC、PCC及FC+PCC减少了输血率和并发症。
  • 作者认为,创伤性凝血病应统一普遍定义。
  • 作者认为,因证据确定性不足,需进一步开展设计良好的试验研究血液成分制品(特别是FC和PCC补充)对创伤性凝血病的疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Death in the early phase of trauma is primarily attributable to uncontrolled bleeding exacerbated by trauma-induced coagulopathy (TIC). A comprehensive synthesis of the available evidence on interventions for TIC is needed. Methods: We conducted a systematic review and meta-analysis of blood component products and tranexamic acid administrations for severe trauma patients with TIC. We included randomized and nonrandomized controlled trials. We included studies with patients who required transfusion with any coagulopathy associated with trauma and a detailed definition. The intervention was administration of blood component products and tranexamic acid. The primary outcome of the study was all-cause mortality and transfusion quantity. Results: Four randomized controlled trials and seven observational studies were included in the qualitative synthesis. In this study, fibrinogen concentrate (FC), prothrombin coagulation cofactor (PCC), and Combination administrations of FC and PCC (FC + PCC) administration did not significantly reduce mortality rates. FC, PCC, and FC + PCC administrations significantly reduced RBC transfusions after admission. In addition, PCC administration reduced FFP transfusions during hospital admission. The incidence of thrombotic events was not significantly higher in the FC + PCC, PCC, and rFVIIa groups. Although statistically nonsignificant, multiple organ failure was lower in the FC and FC + PCC groups. Conclusions: FC and PCC administrations did not significantly reduce mortality. However, FC, PCC, and FC + PCC reduced transfusion rates and complications in patients with coagulopathy-associated trauma. However, the definition of TIC is quite heterogeneous. Thus, the definition of TIC should be defined universally. Furthermore, because of the lack of high certainty of evidence, further well-constructed trials are warranted to investigate the efficacy of blood component products, specifically FC and PCC supplementation for TIC.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Itagaki Y, Hayakawa M, Takahashi Y, et al. THE EFFICACY OF COAGULATION FACTOR CONCENTRATES IN THE MANAGEMENT OF PATIENTS WITH TRAUMA-INDUCED COAGULOPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS. Shock. 2024. PMID: 39715048. doi:10.1097/SHK.0000000000002534

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。